FranΓ§aisπ See the interactive version (live chart) β
| Metric | Value | What it means |
|---|---|---|
| P/E (price / earnings) | β | The higher, the more growth the market expects. |
| Forward P/E | -30.6 | On next year's expected earnings. Lower than current P/E = rising earnings. |
| PEG (P/E Γ· growth) | β | Below 1 = cheap given growth; above 2 = expensive. |
| Net margin | -141% | Share of revenue that ends up as profit. |
| Revenue growth | 2% | Pace of revenue growth. |
| Price-to-book | 8.4 | Price relative to book value. |
| Market cap | $57.0 B | Total market value of the company. |
| Dividend yield | β | No dividend currently. |
| Year | Revenue | Net income | Net margin |
|---|---|---|---|
| 2022 | $19.3 B | $8.4 B | 43% |
| 2023 | $6.8 B | $-4.7 B | -69% |
| 2024 | $3.2 B | $-3.6 B | -110% |
| 2025 | $1.9 B | $-2.8 B | -145% |
π Open the interactive Moderna page (charts, live news) β
Moderna has a P/E of β (forward P/E -30.6) and a PEG of β. A PEG below 1 is rather cheap given growth, above 2 is expensive. Verdict: valuation to review.
Moderna's net margin is about -141% β the share of revenue that ends up as net profit.
Latest known revenue: $1.9 B for net income of $-2.8 B. The year-by-year breakdown is in the income statement above.
Moderna (MRNA) has a market cap of about $57.0 B.
No, Moderna does not currently pay a dividend (it reinvests earnings).
JPI Invest aggregates analyst recommendations across the entire S&P 500 (plus the S&P MidCap 400), replays them against real prices and measures who predicts best β on results, not reputation. Instead of taking a price target at face value, you see each analyst's track record on each stock.
Explore JPI Invest for free β How it works: the method β
β οΈ Educational information, not investment advice. Data: Yahoo Finance, recomputed by JPI Invest. A stock can be Β« cheap Β» for a bad reason.